{"id":"NCT04026113","sponsor":"AbbVie","briefTitle":"Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)","officialTitle":"A Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Safety and Efficacy Study of Linaclotide in Pediatric Participants, Ages 6 to 17 Years, With Irritable Bowel Syndrome With Constipation (IBS-C) and of Linaclotide Versus Placebo in Pediatric Participants With Functional Constipation (FC)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-10-01","primaryCompletion":"2024-05-20","completion":"2024-05-29","firstPosted":"2019-07-19","resultsPosted":"2024-11-26","lastUpdate":"2024-11-26"},"enrollment":438,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Functional Constipation","Irritable Bowel Syndrome With Constipation"],"interventions":[{"type":"DRUG","name":"Linaclotide","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"FC Participants: Placebo","type":"EXPERIMENTAL"},{"label":"FC Participants: Linaclotide 72 μg","type":"EXPERIMENTAL"},{"label":"IBS-C Participants: Linaclotide 145 μg","type":"EXPERIMENTAL"},{"label":"IBS-C Participants: Linaclotide 290 μg","type":"EXPERIMENTAL"}],"summary":"The objective of LIN-MD-64 is to evaluate the safety and efficacy of 12 weeks of linaclotide therapy (72 μg daily) in comparison with placebo in pediatric participants, 6 to 17 years of age, who fulfill modified Rome III Criteria for child/adolescent FC. The objective of LIN-MD-64 is to evaluate the safety and efficacy of 12 weeks of linaclotide therapy (145 μg or 290 μg daily) in pediatric participants 7 to 17 years of age, who fulfill the Rome III criteria for child/adolescent IBS and modified Rome III criteria for child/adolescent FC.","primaryOutcome":{"measure":"Functional Constipation (FC) Participants: Change From Baseline in 12-week SBM (Spontaneous Bowel Movement) Frequency Rate (SBMs/Week) During the Study Intervention Period","timeFrame":"Baseline, up to 12 weeks","effectByArm":[{"arm":"FC Participants: Placebo","deltaMin":1.05,"sd":0.187},{"arm":"FC Participants: Linaclotide 72 μg","deltaMin":2.22,"sd":0.187}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"},{"comp":"OG000 vs OG001","p":"0.4323"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":13,"exclusionCount":21},"locations":{"siteCount":115,"countries":["United States","Belgium","Bulgaria","Canada","Estonia","Germany","Israel","Italy","Netherlands","Poland","Puerto Rico","Spain","Ukraine","United Kingdom"]},"refs":{"pmids":["38211604"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":166},"commonTop":["DIARRHOEA","COVID-19","ABDOMINAL PAIN","CONSTIPATION"]}}